The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection

Who May Qualify: - Aged ≥18 years (inclusive of the boundary value), with no restriction on gender. - Expected survival time of at least 3 months. - Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options. - Meet the requirements for liver and kidney function, as well as cardiopulmonary function. - Free from severe psychiatric disorders. - Able to understand the trial and have signed the willing to sign a consent form form. Who Should NOT Join This Trial: - A history of malignant tumors other than relapsed/refractory autoimmune conditions (where your immune system attacks your own body)s (R/R AID) within 5 years prior to screening. - Subjects with positive results in virus/syphilis tests. - Severe cardiac diseases or unstable systemic diseases. - Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening. - Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion. - Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening. - Subjects who participated in other clinical studies within 1 month before screening. - Other conditions deemed unsuitable for enrollment by the investigator. Always talk to your doctor about whether this trial is right for you.